DK1750668T3 - Liquids containing suspended glass particles - Google Patents

Liquids containing suspended glass particles

Info

Publication number
DK1750668T3
DK1750668T3 DK05731023.7T DK05731023T DK1750668T3 DK 1750668 T3 DK1750668 T3 DK 1750668T3 DK 05731023 T DK05731023 T DK 05731023T DK 1750668 T3 DK1750668 T3 DK 1750668T3
Authority
DK
Denmark
Prior art keywords
glass particles
liquids containing
particles
containing suspended
suspended glass
Prior art date
Application number
DK05731023.7T
Other languages
Danish (da)
Inventor
Bruce Joseph Roser
Original Assignee
Nova Bio Pharma Technologies L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nova Bio Pharma Technologies L filed Critical Nova Bio Pharma Technologies L
Priority claimed from PCT/GB2005/050050 external-priority patent/WO2005099669A1/en
Application granted granted Critical
Publication of DK1750668T3 publication Critical patent/DK1750668T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Glass Compositions (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutical composition comprising a biologically active agent preserved in particulate form, in particular a glass or amorphous particle, such as a sugar, a metal carboxylate, an amino acid or calcium phosphate, wherein said particles are suspended in at least one of a hydrofluoroether, a perfluoroether, a hydrofluoroamine, a perfluoroamine, a hydrofluorothioether, a perfluorothioether, a hydrofluoropolyether or a perfluoropolyether. The use of such fluorinated liquid media overcomes the problem of aggregation of particles and also is environmentally friendly.
DK05731023.7T 2004-04-13 2005-04-13 Liquids containing suspended glass particles DK1750668T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0408199.8A GB0408199D0 (en) 2004-04-13 2004-04-13 Liquids containing suspended sugar glass particles
GB0504501A GB2413075B (en) 2004-04-13 2005-03-07 Liquids containing suspended glass particles
PCT/GB2005/050050 WO2005099669A1 (en) 2004-04-13 2005-04-13 Liquids containing suspended glass particles

Publications (1)

Publication Number Publication Date
DK1750668T3 true DK1750668T3 (en) 2010-05-10

Family

ID=32320732

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05731023.7T DK1750668T3 (en) 2004-04-13 2005-04-13 Liquids containing suspended glass particles

Country Status (10)

Country Link
CN (1) CN1942171B (en)
AT (1) ATE457717T1 (en)
DE (1) DE602005019398D1 (en)
DK (1) DK1750668T3 (en)
ES (1) ES2339783T3 (en)
GB (2) GB0408199D0 (en)
MX (1) MXPA06011895A (en)
PT (1) PT1750668E (en)
RU (1) RU2363447C2 (en)
ZA (1) ZA200609158B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0517688D0 (en) * 2005-08-31 2005-10-05 Cambridge Biostability Ltd Improvements in the stabilisation of biological materials
GB0523638D0 (en) 2005-11-21 2005-12-28 Cambridge Biostability Ltd Pharmaceutical device for the administration of substances to patients
US9243626B2 (en) 2012-11-19 2016-01-26 Nordson Corporation Adhesive dispensing system and method including a pump with integrated diagnostics

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07258027A (en) * 1994-03-16 1995-10-09 Shiseido Co Ltd Makeup cosmetic
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6190701B1 (en) * 1999-03-17 2001-02-20 Peter M. Ronai Composition and method for stable injectable liquids
AU2046101A (en) * 1999-11-22 2001-06-04 Universal Preservation Technologies, Inc. Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
AU2001211986B2 (en) * 2000-10-13 2007-04-26 Cambridge Biostability Ltd. Composition and method for stable injectable liquids

Also Published As

Publication number Publication date
DE602005019398D1 (en) 2010-04-01
PT1750668E (en) 2010-04-07
GB2413075A (en) 2005-10-19
CN1942171A (en) 2007-04-04
GB0408199D0 (en) 2004-05-19
ZA200609158B (en) 2008-06-25
MXPA06011895A (en) 2007-11-20
GB2413075B (en) 2009-01-21
RU2006137275A (en) 2008-05-20
RU2363447C2 (en) 2009-08-10
CN1942171B (en) 2011-04-06
GB0504501D0 (en) 2005-04-13
ATE457717T1 (en) 2010-03-15
ES2339783T3 (en) 2010-05-25

Similar Documents

Publication Publication Date Title
Kim et al. Synthesis and characterization of injectable poly (N-isopropylacrylamide-co-acrylic acid) hydrogels with proteolytically degradable cross-links
HK1135609A1 (en) Formation of medically useful gels comprising microporous particles and methods of use
ATE529499T1 (en) GRANULES OF A SENSITIVE DETERGENT OR CLEANING INGREDIENT
CO5660273A2 (en) PROTEIN AND HIGH CONCENTRATION ANTIBODY FORMULATIONS
GB2464038A (en) System, method, and apparatus for combined fracturing treatment and scale inhibition
GEP20125628B (en) Pharmaceutical compositions containing antagonist anti-cd40 antibody
GB2431403A (en) Capture and removal of biomolecules from body fluids using partial molecular imprints
DE502005009045D1 (en) MAGNETORHEOLOGICAL MATERIALS WITH HIGH SWITCHING FACTOR AND ITS USE
EP2335575A3 (en) Magnetic gas bubble composition and magnetic gas bubble precursor for its manufacture
BR0214279A (en) Pharmaceutical compositions in particulate form
TR200801337T1 (en) Compositions containing poorly water soluble pharmaceutical agents and antimicrobial agents.
DE602005015229D1 (en) MEDICAL ARTICLES MADE OF MIXED POLYMER PARTICLES IN MEANS OF ACTIVE SUBSTANCES
EA200701884A1 (en) FOOD LIPID COMPOSITION IN THE FORM OF PARTICLES
ATE546130T1 (en) DISPERSION OF POLYMER PARTICLES
WO2007111681A3 (en) Device and methods for liquid crystal-based bioagent detection
ATE413419T1 (en) NEW HYDRGELS BASED ON POLYVINYL ALCOHOLS AND POLYVINYL ALCOHOL COPOLYMERS
EA200802140A1 (en) LIQUID COMPOSITION CONTAINING THE ASPARAGIN PROTEAS
DK1750668T3 (en) Liquids containing suspended glass particles
DE60234945D1 (en) POWDER FOR NASAL ADMINISTRATION OF ACTIVE SUBSTANCES
Moelants et al. Citrullination and proteolytic processing of chemokines by Porphyromonas gingivalis
EA201070746A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING AT LEAST ONE PROTEIN ACTIVE INGREDIENT PROTECTED AGAINST DIVISION INGREDIENT
TR200102988T2 (en) Absorbents for use in handling complex liquids.
DE602007005146D1 (en) AMMENSETZUNG
MX2007005124A (en) Spontaneously dispersible pharmaceutical compositions.
De Leon-Oliva et al. Advanced Hydrogel-Based Strategies for Enhanced Bone and Cartilage Regeneration: A Comprehensive Review